Health
Johnson & Johnson enters surgical robotics market following FDA clearance for Ottava system
CNBC reports that regulators approved the device for multiple operations, though analysts question its market impact.
The short version
- Johnson & Johnson gained FDA clearance for its Ottava robotic platform across several general surgery procedures.[CNBC]
- The clearance introduces a new challenger to a domestic market estimated by Precedence Research to reach $18.75 billion by 2035.[CNBC]
- Medtronic previously secured clearance for its Hugo system in December 2025 as major healthcare companies expand robotic offerings.[CNBC]
- Market analysts remain cautious regarding how much market share Ottava will capture in soft-tissue surgery.[CNBC]
Key facts
- The FDA approved Johnson & Johnson's Ottava surgical robot for several general surgery applications.[CNBC]
- Precedence Research estimates the domestic market for surgical robotics will expand from about $4.4 billion in 2025 to $18.75 billion by 2035.[CNBC]
- Medtronic received FDA clearance for its rival Hugo robotic platform in December 2025.[CNBC]
What remains uncertain
- Financial analysts express doubt over the scale of adoption and competitive impact Ottava will achieve in soft-tissue operations.[CNBC]
Sources
Outlet counts describe coverage, not independent confirmation. Reports may share a wire service or original source.